MAWAG
RVMD icon

Mid-American Wealth Advisory Group’s Revolution Medicines RVMD Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21
Closed -$773 – 258
2025
Q2 		$773 Buy
+21
New +$807 ﹤0.01% 299

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Mid-American Wealth Advisory Group's RVMD Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Revolution Medicines (RVMD) in Q3 2025, closing a stake of 21 shares — an estimated $773 sold.

Mid-American Wealth Advisory Group first reported a position in RVMD in Q2 2025 and held it in 1 quarter. The position peaked at $773 in Q2 2025. 323 funds tracked by Wall St. Rank hold RVMD as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Revolution Medicines position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 21 Revolution Medicines shares in Q3 2025, an estimated $773.
  • Mid-American Wealth Advisory Group first reported a position in Revolution Medicines in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Revolution Medicines position peaked at $773 in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.